Current perspectives on therapeutic antibodies

Soomin Yoon, Yong Sung Kim, Hyunbo Shim, Junho Chung

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy.

Original languageEnglish
Pages (from-to)709-715
Number of pages7
JournalBiotechnology and Bioprocess Engineering
Issue number5
StatePublished - Oct 2010


  • efficacy
  • immunogenicity
  • serum half-life
  • therapeutic monoclonal antibody


Dive into the research topics of 'Current perspectives on therapeutic antibodies'. Together they form a unique fingerprint.

Cite this